CMND Clearmind Medicine Inc.

Nasdaq clearmindmedicine.com


$ 0.28 $ -0.06 (-17.62 %)    

Friday, 14-Nov-2025 15:54:37 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 0.2852
$ 0.31
$ 0.28 x 1,300
$ 0.29 x 1,600
$ 0.28 - $ 0.32
$ 0.24 - $ 2.18
9,085,250
na
nm
$ 0.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clearmind-medicine-cmnd-stock-soars-thursday-whats-going-on

Clearmind Medicine Inc (NASDAQ:CMND) shares are trading higher on Thursday. Here's a look at what you need to know.

 clearmind-receives-final-approval-from-hadassah-medical-center-jerusalem-for-ongoing-phase-12a-clinical-trial-evaluating-cmnd-100-proprietary-meai-based-oral-drug-candidate-for-aud-treatment

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-medicine-announces-cnipa-publication-of-patent-for-meai-compound-in-depression-treatment

The notice was received by the China National Intellectual Property AdministrationVancouver, Canada, Nov. 12, 2025 (GLOBE NEWSW...

 clearmind-medicine-completes-first-patient-cohort-in-phase-iiia-trial-of-meai-based-cmnd-100-for-alcohol-use-disorder

Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion...

 why-is-clearmind-stock-down-today

Shares of Clearmind Medicine Inc. (NASDAQ: CMND) are falling Friday after the clinical-stage biotech company shared a key updat...

 clearmind-medicine-receives-nasdaq-delisting-notification

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech co...

 clearmind-expands-meai-patent-protection-with-new-south-korea-filing-advancing-global-depression-treatment-strategy

Patent expands MEAI's global intellectual property protection as Clearmind advances clinical development and commercializat...

 clearmind-medicine-says-last-patient-of-first-cohort-in-phase-iiia-clinical-trial-evaluating-cmnd-100-receives-treatment-fda-approved-clinical-protocol

Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion...

 clearmind-medicine-enrolls-last-patient-for-first-cohort-of-phase-iiia-clinical-trial-evaluating-cmnd-100-proprietary-meai-based-oral-drug-candidate-for-aud-treatment

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION